ES2151665T3 - Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno. - Google Patents

Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno.

Info

Publication number
ES2151665T3
ES2151665T3 ES96919762T ES96919762T ES2151665T3 ES 2151665 T3 ES2151665 T3 ES 2151665T3 ES 96919762 T ES96919762 T ES 96919762T ES 96919762 T ES96919762 T ES 96919762T ES 2151665 T3 ES2151665 T3 ES 2151665T3
Authority
ES
Spain
Prior art keywords
tumour
cells
therapeutic response
sample
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96919762T
Other languages
English (en)
Inventor
Leif Hakansson
Annika Hakansson
Bertil Gustafsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Landstinget I Ostergotland
Original Assignee
Landstinget I Ostergotland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landstinget I Ostergotland filed Critical Landstinget I Ostergotland
Application granted granted Critical
Publication of ES2151665T3 publication Critical patent/ES2151665T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION TRATA DE UN PROCEDIMIENTO PARA PREDECIR LA RESPUESTA TERAPEUTICA DE UN FARMACO CONTRA UN TUMOR MALIGNO EN UN PACIENTE HUMANO UTILIZANDO UNA MUESTRA DE UN ASPIRADO REALIZADO CON UNA AGUJA FINA DEL TUMOR DE UN PACIENTE. EL PROCEDIMIENTO INCLUYE LAS ETAPAS DE IDENTIFICAR Y ESTIMAR EN UNA MUESTRA EL NUMERO DE CELULAS QUE PERTENECEN A UNA CLASE DE CELULAS EN RELACION CON OTRAS CELULAS EN LA MUESTRA, Y COMPARAR LA ESTIMACION CON UN ANALISIS REALIZADO PREVIAMENTE PARA DEMOSTRAR LA CORRELACION ENTRE EL NUMERO DE CELULAS Y LOS PARAMETROS DE LA RESPUESTA TERAPEUTICA DEL FARMACO DIRIGIDO CONTRA EL TUMOR EN PACIENTES HUMANOS, SIENDO LOS RESULTADOS DE LA COMPARACION INDICATIVOS DE LA RESPUESTA TERAPEUTICA DEL FARMACO EN UN PACIENTE HUMANO. UN ESTUCHE DE ENSAYO DE DIAGNOSTICO INCLUYE UNA MEZCLA DE ENZIMAS QUE TRANSFORMA LA MUESTRA DEL TUMOR EN UNA SUSPENSION DE UNA SOLA CELULA, UNA PRIMERA MEZCLA DE ANTICUERPOS MONOCLONALES DIRIGIDOS CONTRA ANTIGENOS ASOCIADOS AL TUMOR QUE SE ENCUENTRAN SOBRE LAS CELULAS TUMORALES EN LA SUSPENSION DE UNA SOLA CELULA, TENIENDO DICHOS ANTICUERPOS UN PRIMER MARCADOR, Y UNA SEGUNDA MEZCLA DE DOS TIPOS DE ANTICUERPOS MONOCLONALES DIRIGIDOS CONTRA DOS ANTIGENOS ESPECIFICOS QUE SE ENCUENTRAN SOBRE LINFOCITOS, TENIENDO DICHOS ANTICUERPOS UN SEGUNDO Y UN TERCER MARCADOR, RESPECTIVAMENTE.
ES96919762T 1995-05-12 1996-05-10 Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno. Expired - Lifetime ES2151665T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501782A SE9501782D0 (sv) 1995-05-12 1995-05-12 Method of predicting the therapeutic response of a drug against a malignant tumour

Publications (1)

Publication Number Publication Date
ES2151665T3 true ES2151665T3 (es) 2001-01-01

Family

ID=20398299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96919762T Expired - Lifetime ES2151665T3 (es) 1995-05-12 1996-05-10 Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno.

Country Status (12)

Country Link
US (1) US6114128A (es)
EP (1) EP0824696B1 (es)
JP (1) JPH11504715A (es)
AT (1) ATE196688T1 (es)
CA (1) CA2215627A1 (es)
DE (1) DE69610496T2 (es)
DK (1) DK0824696T3 (es)
ES (1) ES2151665T3 (es)
GR (1) GR3034891T3 (es)
PT (1) PT824696E (es)
SE (1) SE9501782D0 (es)
WO (1) WO1996035949A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824467A (en) * 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
US6087090A (en) * 1997-02-25 2000-07-11 Celtrix Pharmaceuticals, Inc. Methods for predicting drug response
US20030096237A1 (en) * 2000-08-28 2003-05-22 Ulrich Certa Determination of the ability of patients to respond to a tumor treatment
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
SI2490694T1 (sl) 2009-10-19 2015-12-31 Rostaquo S.P.A. Rostafuroksin za farmakogenomsko zdravljenje kardiovaskularnih stanj
US20130216557A1 (en) * 2010-08-14 2013-08-22 Biogen Idec Ma Inc. Ltbr blockade: methods for optimizing therapeutic responsiveness of patients

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
CA1296622C (en) * 1986-08-12 1992-03-03 Jeffrey E. Anderson Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system

Also Published As

Publication number Publication date
PT824696E (pt) 2001-03-30
SE9501782D0 (sv) 1995-05-12
GR3034891T3 (en) 2001-02-28
EP0824696B1 (en) 2000-09-27
CA2215627A1 (en) 1996-11-14
EP0824696A1 (en) 1998-02-25
DE69610496T2 (de) 2001-05-10
DK0824696T3 (da) 2001-01-02
JPH11504715A (ja) 1999-04-27
DE69610496D1 (de) 2000-11-02
WO1996035949A1 (en) 1996-11-14
ATE196688T1 (de) 2000-10-15
US6114128A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
BR9917218A (pt) Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas
SE9600820D0 (sv) Antibodies and their use
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
ATE155820T1 (de) Prüfung zur vorhersage des ergebnisses von ivf
AU4694499A (en) Trace level detection of analytes using artificial olfactometry
DK0559795T3 (da) Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen
CA1305928C (en) Monoclonal antibody specific to a novel epitope of the lfa-1 antigen of human t lymphocytes
AU7398996A (en) Multiplexed analysis of clinical specimens apparatus and method
AU2738195A (en) Tumor diagnosis and prognosis
ATE443147T1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
SE9500023D0 (sv) Method of detecting cancer
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
Bloom et al. In vitro methods in cell-mediated immunity: a progress report
ES2151665T3 (es) Procedimiento y equipo para predecir la respuesta terapeutica de un farmaco contra un tumor maligno.
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
DE69839876D1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
OA08331A (fr) Anticorps monoclonaux, lignées de cellules et trousses les contenant pour diagnostiquer les épithéliomas de poumons humains ne comportant pas de petites cellules;
Nicolson et al. Growth of rat mammary adenocarcinoma cells in semisolid clonogenic medium not correlated with spontaneous metastatic behavior: heterogeneity in the metastatic, antigenic, enzymatic, and drug sensitivity properties of cells from different sized colonies
ATE382678T1 (de) Verfahren zur diagnose von rickettsia pulicis
DE69731219D1 (de) Beurteilung von cerrixzellen
SE9501780D0 (sv) Monitoring immunotherapy of malignant tumours
WO2001029255A3 (en) Diagnostic test for cephalic pain
GODFREY et al. SOME RECENT THESES ON THE THYMUS AND RELATED TOPICS

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 824696

Country of ref document: ES